Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

被引：7

作者：

Kucine, Nicole ^{[1
]}

Bergmann, Shayla ^{[2
]}

Krichevsky, Spencer ^{[3
]}

Jones, Devin ^{[4
]}

Rytting, Michael ^{[5
]}

Jain, Juhi ^{[6
]}

Bennett, Carolyn M. ^{[6
]}

Resar, Linda M. S. ^{[7
,8
,9
]}

Mascarenhas, John ^{[4
]}

Verstovsek, Srdan ^{[10
]}

Hoffman, Ronald ^{[4
]}

机构：

[1] Weill Cornell Med, Dept Pediat, New York, NY USA

[2] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA

[3] Weill Cornell Med, Richard T Silver Myeloproliferat Neoplasm Ctr, New York, NY USA

[4] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, New York, NY 10029 USA

[5] Lakeshore Hlth Partners, Holland, MI USA

[6] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta,Aflac Canc & Blood D, Atlanta, GA USA

[7] Johns Hopkins Univ SOM, Dept Med, Div Hematol, Baltimore, MD USA

[8] Johns Hopkins Univ SOM, Dept Oncol, Div Hematol, Baltimore, MD USA

[9] Johns Hopkins Univ SOM, Dept Pathol, Div Hematol, Baltimore, MD USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

PEDIATRIC BLOOD & CANCER | 2021年 / 68卷 / 03期

关键词：

essential thrombocytosis; interferon; myeloproliferative neoplasm; polycythemia vera;

D O I：

10.1002/pbc.28888

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.

引用

页数：4

共 50 条

[41] Updates in the management of polycythemia vera and essential thrombocythemia
Bose, Prithvirai
Verstovsek, Srdan
[J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
[42] Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia
De Stefano, Valerio
Za, Tommaso
Rossi, Elena
Vannucchi, Alessandro M.
Ruggeri, Marco
Elli, Elena
Mico, Caterina
Tieghi, Alessia
Cacciola, Rossella R.
Santoro, Cristina
Gerli, Giancarla
Guglielmelli, Paola
Pieri, Lisa
Scognamiglio, Francesca
Rodeghiero, Francesco
Pogliani, Enrico M.
Finazzi, Guido
Gugliotta, Luigi
Leone, Giuseppe
Barbui, Tiziano
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (02) : 97 - 100
[43] Contemporary approach to essential thrombocythemia and polycythemia vera
Aruch, Daniel
Mascarenhas, John
[J]. CURRENT OPINION IN HEMATOLOGY, 2016, 23 (02) : 150 - 160
[44] Treatment options for essential thrombocythemia and polycythemia vera
Vannucchi, Alessandro M.
Guglielmelli, Paola
Pieri, Lisa
Antonioli, Elisabetta
Bosi, Alberto
[J]. EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (01) : 41 - 55
[45] New drugs in essential thrombocythemia and polycythemia vera
Tefferi, A
Elliott, MA
Solberg, LA
Silverstein, MN
[J]. BLOOD REVIEWS, 1997, 11 (01) : 1 - 7
[46] The risk of thrombosis in essential thrombocythemia and polycythemia vera
Pearson, TC
[J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 16 - 21
[47] DNA METHYLATION IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
Santiago, S.
Miguel, G.
Enriqueta, A.
Ana, A.
Rosa, R.
Joaquin, J.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 404 - 404
[48] Platelet density in essential thrombocythemia and polycythemia vera
Järemo, P
[J]. PLATELETS, 1999, 10 (01) : 61 - 63
[49] Pegylated Interferon-Alfa Suppresses Clonal Hematopoiesis in Polycythemia Vera and Essential Thrombocythemia and Is Associated with Immune Responses to Tumor Antigens
Tashi, Tsewang
Luetkens, Tim
Avila, Stephanie
Kim, Soo Jin
Prchal, Josef T.
[J]. BLOOD, 2019, 134
[50] Therapeutic options for essential thrombocythemia and polycythemia vera
Solberg, LA
[J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 10 - 15

← 1 2 3 4 5 →